Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK716155 subcutaneous injections
GSK716155 injections · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| albiglutide | ACTIVE_COMPARATOR | albiglutide injection |
| albiglutide placebo | PLACEBO_COMPARATOR | placebo injection |
| Group A | EXPERIMENTAL | In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen. |
| Group B | EXPERIMENTAL | In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen. |
| Group C | EXPERIMENTAL | In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen. |
| Group D | EXPERIMENTAL | In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm. |
| Group E | EXPERIMENTAL | In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg. |
| Group F | EXPERIMENTAL | In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen. |
| Group G | EXPERIMENTAL | In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm. |
| Group H | EXPERIMENTAL | In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg. |
| Name | Type | Description |
|---|---|---|
| GSK716155 subcutaneous injections | DRUG | albiglutide subcutaneous injection |
| placebo injection | BIOLOGICAL | placebo injection |
Inclusion criteria: * Subjects must have type 2 diabetes mellitus that has been diagnosed for at least three months. * Must be taking either (1) no medication for their diabetes or (2) taking metformin, a sulfonylurea, or metformin and a sulfonylurea. * Subjects must be willing to wash-out of these...
GSK716155 is an investigational injectable medicine that was studied for the treatment of type 2 diabetes mellitus. It was evaluated in two completed clinical trials, including an injection site study and an inpatient Phase 2 study, both conducted in patients with type 2 diabetes in the United States.
GSK716155 is developed by GSK plc, which trades under the ticker GSK. The company sponsored both clinical trials of the drug in type 2 diabetes mellitus.
GSK716155 reached Phase 2 clinical development for type 2 diabetes mellitus. It is an investigational drug and is not described as approved. Both of its registered trials are completed, and no trials are currently active.
GSK716155 was studied in two completed trials: NCT00394030, a Phase 1 injection site study in patients with type 2 diabetes and healthy volunteers, and NCT00354536, a Phase 2 inpatient study in patients with type 2 diabetes. Together they enrolled 123 participants, all in the United States.
Yes. GSK716155 subcutaneous injections is another name for GSK716155, the same investigational injectable drug developed by GSK plc for type 2 diabetes mellitus. Searches using either name refer to the same asset and the same clinical trial program.
The two completed GSK716155 trials enrolled a total of 123 participants. NCT00394030 enrolled 63 patients with type 2 diabetes and healthy volunteers, and NCT00354536 enrolled 60 patients with type 2 diabetes. Both studies were controlled and randomized, and participants were 18 years or older.